Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Zemimet SR vs Zemiglo + Glucophage XR
NCT04317703Phase 1Completed
- Sponsor
- LG Chem
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Aug 2020; status: completed.
02
Drugs
gemigliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04317703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317703.